| Predictors of costs of care in Alzheimer’s disease: a multinational sample of 1222 patients A Gustavsson, P Brinck, N Bergvall, K Kolasa, A Wimo, B Winblad, ... Alzheimer's & Dementia 7 (3), 318-327, 2011 | 170 | 2011 |
| How to value digital health interventions? A systematic literature review K Kolasa, G Kozinski International Journal of Environmental Research and Public Health 17 (6), 2119, 2020 | 86 | 2020 |
| State of the art in adoption of contact tracing apps and recommendations regarding privacy protection and public health: systematic review K Kolasa, F Mazzi, E Leszczuk-Czubkowska, Z Zrubka, M Péntek JMIR mHealth and uHealth 9 (6), e23250, 2021 | 60 | 2021 |
| Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs K Kolasa, KM Zwolinski, Z Kalo, T Hermanowski Orphanet journal of rare diseases 11, 1-12, 2016 | 55 | 2016 |
| Does cost sharing do more harm or more good?-a systematic literature review K Kolasa, M Kowalczyk BMC Public Health 16, 1-14, 2016 | 42 | 2016 |
| A review of Health Technology Assessment (HTA) recommendations for drug therapies issued between 2007 and 2009 and their impact on policymaking processes in Poland K Kolasa, S Schubert, A Manca, T Hermanowski Health Policy 102 (2-3), 145-151, 2011 | 41 | 2011 |
| Endovascular mechanical thrombectomy versus thrombolysis in patients with iliofemoral deep vein thrombosis–a systematic review and meta-analysis MKW Lichtenberg, S Stahlhoff, K Młyńczak, D Golicki, P Gagne, ... Vasa, 2020 | 36 | 2020 |
| How Much Is the Cost of Multiple Sclerosis–Systematic K Kolasa Przegl Epidemiol 67, 75-85, 2013 | 31 | 2013 |
| The cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland W Grzeszczak, L Czupryniak, K Kolasa, C Sciborski, ID Lomon, ... Diabetes Technology & Therapeutics 14 (1), 65-73, 2012 | 31 | 2012 |
| Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland E Soini, T Hallinen, M Brignone, R Campbell, F Diamand, S Cure, ... Expert Review of Pharmacoeconomics & Outcomes Research 17 (3), 293-302, 2017 | 29 | 2017 |
| Role of health technology assessment in the process of implementation of the EU Transparency Directive: relevant experience from Central Eastern European countries K Kolasa, Z Kalo, V Zah, T Dolezal Expert Review of Pharmacoeconomics & Outcomes Research 12 (3), 283-287, 2012 | 24 | 2012 |
| How can multi criteria decision analysis support value assessment of pharmaceuticals?-findings from a systematic literature review K Kolasa, V Zah, M Kowalczyk Expert Review of Pharmacoeconomics & Outcomes Research 18 (4), 379-391, 2018 | 23 | 2018 |
| Revealed preferences towards the appraisal of orphan drugs in Poland-multi criteria decision analysis K Kolasa, KM Zwolinski, V Zah, Z Kaló, T Lewandowski Orphanet Journal of Rare Diseases 13, 1-14, 2018 | 21 | 2018 |
| Does it matter whose opinion we seek regarding the allocation of healthcare resources?-a case study K Kolasa, T Lewandowski BMC health services research 15, 1-10, 2015 | 21 | 2015 |
| Health technology assessment in Poland and Scotland: comparison of process and decisions K Kolasa, R Wasiak International Journal of Technology Assessment in Health Care 28 (1), 70-76, 2012 | 21 | 2012 |
| Without data, you’re just another person with an opinion K Kolasa, W Goettsch, G Petrova, A Berler Expert Review of Pharmacoeconomics & Outcomes Research 20 (2), 147-154, 2020 | 17 | 2020 |
| A comparison of the burden of out‐of‐pocket health payments in Denmark, Germany and Poland A Zawada, K Kolasa, C Kronborg, D Rabczenko, T Rybnik, JT Lauridsen, ... Global Policy 8, 123-130, 2017 | 17 | 2017 |
| Optymalna alokacja zasobów w ochronie zdrowia K Kolasa Wolters Kluwer Polska, 2021 | 16 | 2021 |
| How useful are digital health terms for outcomes research? An ISPOR special interest group report A Burrell, Z Zrubka, A Champion, V Zah, L Vinuesa, AP Holtorf, ... Value in Health 25 (9), 1469-1479, 2022 | 15 | 2022 |
| What aspects of the health technology assessment process recommended by international health technology assessment agencies received the most attention in Poland in 2008? K Kolasa, M Dziomdziora, L Fajutrao International journal of technology assessment in health care 27 (1), 84-94, 2011 | 15 | 2011 |
